%0 Journal Article
%T 胰高血糖素样肽-1受体激动剂治疗心力衰竭的研究进展<br>Research Progress of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Heart Failure
%A 胡明月
%A 陈运清
%J Advances in Clinical Medicine
%P 314-320
%@ 2161-8720
%D 2025
%I Hans Publishing
%R 10.12677/acm.2025.1571991
%X 心力衰竭(Heart Failure, HF)病理生理机制复杂&#65292;治疗选择有限&#65292;是全球心血管疾病的重要负担。作为代谢性疾病的治疗药物&#65292;胰高血糖素样肽-1受体激动剂(GLP-1RA)近年来被发现对心血管的保护作用显著&#65292;为预防和治疗心力衰竭提供了新的方向。本文将对GLP-1RA治疗心力衰竭的研究进展作一综述。<br>Heart failure (HF) has complex pathophysiological mechanisms and limited treatment options, serving as a significant burden of cardiovascular diseases worldwide. As therapeutic agents for metabolic diseases, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been found to exert remarkable cardiovascular protective effects in recent years, providing a new direction for the prevention and treatment of heart failure. This article reviews the research progress of GLP-1RAs in the treatment of heart failure.
%K 胰高血糖素样肽-1受体激动剂&#65292
%K 心力衰竭&#65292
%K 心血管获益<br>Glucagon-Like Peptide-1 Receptor Agonists
%K Heart Failure
%K Cardiovascular Benefits
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=118887